Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

Development 288

Development Vaccination Vaccine Scientist 288

Pharmaceutical Technology

NOVEMBER 1, 2022

What is Research and Development (R&D)? This category includes organisations that have demonstrated a commitment to the research and development of new products and/or new processes. This category highlights companies that have conducted research into the use of AI and technology for the development of new treatments.

Research 228

Research Development Vaccination Vaccine 228

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccination 276

Vaccination Vaccine Clinical Trials Clinical Trials 276

Pharmaceutical Technology

AUGUST 14, 2023

HebeCell has forged a strategic collaboration with Logomix for researching and developing gene-edited natural killer cells (NK cells).

Gene Editing 246

Gene Editing Gene Development Research 246

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Contract Manufacturing 256

Pharmaceutical Technology

JULY 18, 2023

Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.

Genetics 246

Genetics In-Vivo Genome Genomics 246

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Gene Therapy Development 328

Pharmaceutical Technology

SEPTEMBER 4, 2023

iNtRON's contract is part of the US Army’s DEVCOM strategy to develop drugs to treat antibiotic-resistant UTIs.

Development 246

Development Drugs 246

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Development 259

Development Clinical Trials Clinical Trials Life Science 259

Pharmaceutical Technology

SEPTEMBER 12, 2023

CancerVAX plans to adapt its universal cancer vaccine platform to develop a universal CAR-T cell platform.

Development 264

Development Vaccination Vaccine 264

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.

Drug Delivery 242

Drug Delivery RNA Drugs Gene Therapy 242

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccination 231

Vaccination Vaccine Development Protein 231

Pharmaceutical Technology

APRIL 20, 2023

Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors.

Development 246

Development Drugs Business Development Sales 246

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. The programme is expected to develop long-lasting monoclonal antibodies and expedite the development of vaccines that produce mucosal immunity to reduce transmission and infection risks.

Vaccination 264

Vaccination Vaccine Development Antibody 264

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Lab-specific industrial co-bots can carry out both complex and repetitive tasks such as liquid handling.

Drugs 311

Drugs Pharma Companies Development Clinical Development 311

Pharmaceutical Technology

APRIL 5, 2023

Austrian molecular glue degraders discovery and development company Proxygen and Merck , known as MSD outside the US and Canada, have entered into a multi-year research collaboration and licence deal. Proxygen will receive royalties on net sales of products developed under the partnership.

Development 246

Development Drugs Research Engineer 246

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Genetic Disease Development 242

Pharmaceutical Technology

FEBRUARY 20, 2023

Other lines of research look at the genetic overlap between FTD and amyotrophic lateral sclerosis (ALS), which could be used in the development of treatments for both conditions. This is also one of the major challenges that slow the development of effective treatments for FTD, he adds. Do we develop a single treatment for all three?

Gene Therapy 246

Gene Therapy Gene Development Protein 246

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients. CLDN 18.2).

Clinical Trials 264

Clinical Trials Clinical Trials Development Antibody 264

Pharmaceutical Technology

NOVEMBER 8, 2022

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen.

Gene Therapy 305

Gene Therapy Gene Development Clinical Trials 305

Pharmaceutical Technology

SEPTEMBER 19, 2023

BioNTech has entered a strategic collaboration with the CEPI to develop mRNA-based vaccine candidates for monkeypox (Mpox ) prevention.

Vaccination 130

Vaccination Vaccine Development 130

Pharmaceutical Technology

JANUARY 25, 2023

A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. This proposal will develop novel ER-beta drugs that promote tumour suppression, leading to a new therapeutic modality to treat GBM.”

Research 246

Research Development Clinical Trials Clinical Trials 246

Bio Pharma Dive

MARCH 20, 2023

As new gene therapies are developed to treat a growing number of indications, patients may soon have access to novel treatment options and potential cures.

Gene Therapy 245

Gene Therapy Gene Development Manufacturing 245

Pharmaceutical Technology

MAY 9, 2023

Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Development 261

Development Protein Drugs Research 261

Pharmaceutical Technology

OCTOBER 21, 2022

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.

Development 278

Development Clinical Development Licensing Licensing 278

Bio Pharma Dive

MAY 1, 2023

Founded by Sam Waksal, Graviton Biosciences is developing drugs that block an enzyme called ROCK2, which drew the interest of neurology-focused Ovid.

Drugs 329

Drugs Development 329

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Protein 246

Protein Development RNA Genetics 246

Pharmaceutical Technology

SEPTEMBER 26, 2023

The funding will support the clinical development of the oral SK ion channel inhibitor that was recently evaluated in a Phase II trial.

Clinical Development 130

Clinical Development Development Trials 130

Pharmaceutical Technology

MARCH 29, 2023

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases. The two companies will together research and develop T cell therapies for Crohn’s disease and ulcerative colitis, as well as two other undisclosed indications.

Gene Therapy 245

Gene Therapy Development Gene Research 245

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies.

Vaccination 245

Vaccination Vaccine Gene Therapy Development 245

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The US Food and Drug Administration has granted fast-track designation to SNIPR001, which is currently in clinical development.

Drugs 246

Drugs Bacteria Gene Editing Research 246

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio.

Drugs 246

Drugs Development Clinical Development Medicine 246

Pharmaceutical Technology

APRIL 14, 2023

Twist Bioscience has introduced Twist T-cell receptor (TCR) and Twist chimeric antigen receptor (CAR) libraries to facilitate the development of cell therapies. Researchers will now be able to speed up the creation of tailor-made libraries that can help in identifying and developing new cell therapies.

Gene Therapy 246

Gene Therapy Gene Development Antibody 246

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244

RNA Vaccination Vaccine Development 244